233 related articles for article (PubMed ID: 16917141)
1. Chemoprevention of breast cancer in postmenopausal women.
Geller BA; Vogel VG
Breast Dis; 2005-2006; 24():79-92. PubMed ID: 16917141
[TBL] [Abstract][Full Text] [Related]
2. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
3. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
5. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
6. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of breast cancer.
Cuzick J
Breast Cancer; 2008; 15(1):10-6. PubMed ID: 18224388
[TBL] [Abstract][Full Text] [Related]
8. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
10. Update on breast cancer prevention.
Rastogi P; Vogel VG
Oncology (Williston Park); 2003 Jun; 17(6):799-805; discussion 808-10, 813. PubMed ID: 12846124
[TBL] [Abstract][Full Text] [Related]
11. Current concepts in breast cancer chemoprevention.
Chlebowski RT
Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
13. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of breast cancer.
Zelnak AB; O'Regan RM
Curr Probl Cancer; 2004; 28(4):201-17. PubMed ID: 15318323
[No Abstract] [Full Text] [Related]
15. Pharmacological prevention of breast cancer: quo vadis?
Serrano D; Bonanni B; Cazzaniga M; Galli A; Gonzaga AG; Decensi A
Breast; 2003 Dec; 12(6):379-86. PubMed ID: 14659109
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
[TBL] [Abstract][Full Text] [Related]
17. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer chemoprevention: current clinical practice and future direction.
Bevers TB
Biomed Pharmacother; 2001 Nov; 55(9-10):559-64. PubMed ID: 11769967
[TBL] [Abstract][Full Text] [Related]
19. Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Lo SS; Vogel VG
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):97-111. PubMed ID: 14687600
[TBL] [Abstract][Full Text] [Related]
20. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]